Genzyme, Sanofi at Odds Over Start Price

Sanofi-Aventis' talks to acquire Genzyme are continuing but the companies disagree on a 'threshold' price at which Sanofi could begin due diligence on Genzyme, a report says.
Author:
Publish date:

CAMBRIDGE, Mass. (

TheStreet

) --

Sanofi-Aventis'

(SNY) - Get Report

talks to acquire

Genzyme

(GENZ)

are continuing but the companies disagree on a "threshold" price at which Sanofi could begin due diligence on Genzyme, a report says.

The threshold price has been a sticking point in recent talks and the main reason why the talks haven't progressed further, the

Wall Street Journal

reports, citing people familiar with the matter.

Genzyme could open its books to Sanofi if the French company was to offer around $75 a share as a starting point for talks on a possible sale, the

Journal

says. But Genzyme, the U.S. generics drugmaker, probably won't sell unless a bid hits at least $80 a share, people familiar with the matter said.

Sanofi's initial offer

was $69 a share, or $18.4 billion. Some Genzyme shareholders have called the offer "lackluster."

Sanofi was considering whether to go "hostile" on its offer recently, but the two sides have decided to remain in friendly talks for now, the people said, the

Journal

reports.

Genzyme shares closed Monday at $67.75.

-- Reported by Joseph Woelfel in New York.

Get more stock ideas and investing advice on our sister site,

Stockpickr.com.